← Analysis page  ·  Pieter Slegers hub  ·  Research hub

Actionable insights — Why you should invest in boring companies

A three-question durability screen you can apply in a minute, and the discipline of separating a quality verdict from a price verdict.
2026-FEB-17 · Compounding Quality (Substack, free post) · Pieter Slegers · read ↗ · full analysis · transcript
How to read this page: each insight is a method used in this issue, written so it can be rerun on other names. Written post, so no timestamps.

1. Screen for durability with three questions before opening a spreadsheet

The repeatable method
  1. Is it essential? Would the customer's operation actually stop, or break a rule, without this product? Nice-to-have fails.
  2. Does it have a replacement? Not "is there a competitor" but "could the customer switch at acceptable cost and risk." Retraining, revalidation and migration are the real barriers.
  3. Is the cash flow stable and predictable? Look for recurring consumption — consumables, service contracts, subscriptions — rather than repeat one-off sales.
  4. Only names passing all three earn the financial work. The screen is deliberately fast because its job is to shorten the list.
Here: "They are essential / They have no replacement / They generate a stable and predictable cash flow." ISRG passes all three — surgery cannot be undone mid-protocol, a trained theatre team cannot switch systems cheaply, and instruments plus service recur with every procedure.
Watch for

2. Value an installed base, not a unit sale

The repeatable method
  1. Split revenue into the equipment sale and everything the equipment consumes afterwards — instruments, accessories, service, software.
  2. Treat each unit sold as an annuity opening rather than a transaction closing: the metric that matters is procedures per installed system, not systems sold.
  3. Check that the recurring part is genuinely tied to the machine (proprietary consumables, service the maker controls) rather than open to third parties.
  4. Then ask what happens if unit sales stall — a strong installed base keeps compounding through a placement slowdown.
Here: ISRG — "It generates recurring revenue from instruments, accessories, and service contracts used in every procedure… every time a hospital buys a robotic surgery system, ISRG gets a new customer for life."
Watch for

3. Publish the multiple even when you are not making a valuation call

The repeatable method
  1. Make the quality case with its own evidence: margins, returns on capital, balance sheet, long-run shareholder return.
  2. State the current multiple in the same block of numbers, so the reader is never given quality without price.
  3. If you are not taking a valuation view, say the pitch is about the business — do not let the omission read as endorsement.
  4. Keep the entry discipline separate and explicit, as the archive does elsewhere (Cintas: a stated 25x forward entry; HEICO: a published pass at 53-57x).
Here: ISRG is disclosed with net cash, a 28.4% net margin, an 18.4% ROIC, a +26.6% CAGR since 2001 — and a 47.8x forward PE, in an issue devoted to buying dull businesses cheaply. No verdict is offered on the multiple.
Watch for

4. Match the temperament to the strategy, and design for boredom

The repeatable method
  1. Accept that a portfolio of essential, predictable businesses will produce very little to do — that is the design, not a failure of it.
  2. Separate the desire for action from the investment process; route it somewhere it cannot cost money.
  3. Build a cadence (monthly adds, a monthly ratings sheet) so that activity is scheduled rather than triggered by news.
Here: "Investing is simple, but not easy. It should be very boring. Like watching paint dry or grass grow. If you want excitement, you should go to Las Vegas." The practice of it in the same month: fixed monthly adds on 1 February and 22 February.
Watch for

5. Check a cited track record against your own previous citation of it

The repeatable method
  1. When you quote an investor's record, note what exactly is being measured — a live fund, a backtest of a formula, gross or net of fees — and over which window.
  2. Keep the same figure across issues, or explain the difference when it changes.
  3. Treat a backtested formula return and a realised fund return as different classes of evidence, because they are.
Here: Greenblatt's Magic Formula is cited as "a return of 33% (!) per year" between 1985 and 2005 — five days after the 12 February issue cited "a yearly return of +40% (!) for over 20 years" for the same investor over the same span.
Watch for

Methods distilled from the archived Compounding Quality post for personal study. Not investment advice.